On February 7, 2023 Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, reported that Company’s Management will provide a corporate update and participate in one-on-one investor meetings at the SVB Securities Global Biopharma Conference, to be held virtually from February 14-16, 2023 (Press release, Selecta Biosciences, FEB 7, 2023, View Source [SID1234626930]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
SVB Securities Global Biopharma Conference
Format: Corporate update and one-on-one investor meetings
Presentation Date: Tuesday, February 14, 2023
Presentation Time: 8:00 a.m. ET
Webcast: Click Here
To schedule a meeting with the Company, please contact your SVB Securities representative.
An archived webcast will also be accessible in the Investors & Media section of the company’s website at www.selectabio.com.